Search Within

Weinberg Fellows

  1. "Dean Bajorin"
Formats
  1. Meeting Abstract (61)
  2. Journal Article (38)
  3. Book Section (1)
  4. Editorial (1)
  5. Research Letter (1)
Groups
  1. Department of Medicine (102)
  2. Genitourinary Oncology Service (102)
  3. Hematology-Oncology Fellows (102)
  4. Solid Tumor Oncology Division (102)
  5. Department of Pathology and Laboratory Medicine (72)
  6. Epidemiology and Biostatistics (59)

More Groups

People
  1. Dean Bajorin (102)
  2. Samuel Funt (90)
  3. Jonathan Rosenberg (70)
  4. Gopakumar Iyer (68)
  5. Hikmat Al-Ahmadie (50)
  6. Min Yuen Teo (47)

More People

Years
  1. 2025 (5)
  2. 2024 (9)
  3. 2023 (6)
  4. 2022 (15)
  5. 2021 (15)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (59)
  2. Cancer Research (4)
  3. Annals of Oncology (3)
  4. Clinical Cancer Research (3)
  5. JCO Precision Oncology (3)
  6. European Urology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (62)
  2. American Association for Cancer Research (8)
  3. Nature Publishing Group (7)
  4. Oxford University Press (4)
  5. Wiley Blackwell (3)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (102)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cutaneous toxicity and clinical outcomes with enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma
    Meeting Abstract

    Arbuiso, A.; Sternschuss, M.; Whiting, K.; Gupta, A.; Huttenlocher Bent, E.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Treatment patterns and clinical outcomes with platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in patients with metastatic urothelial carcinoma
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Arbuiso, A.; Gupta, A.; Bent, E. H.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma
    Journal Article

    Sternschuss, M.; Toumbacaris, N.; Das, J. P.; Powles, T.; Kotecha, R. R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N. M.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors
    Journal Article

    Matulewicz, R. S.; Baky, F.; Liso, N.; Williams, B. M.; Porwal, S.; Assel, M.; Carver, B. S.; Bajorin, D. F.; Motzer, R. J.; Bosl, G. J.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Characterizing the immune effects of enfortumab vedotin (EV) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC)
    Meeting Abstract

    Gupta, A.; Sevilla, C.; Pihlstrom, N. L.; Liang, S.; Regazzi, A. M.; McCoy, A. S.; Maher, C. A.; Wong, P.; Ahmed, F.; Funt, S. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer
    Meeting Abstract

    Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes
    Meeting Abstract

    Shah, N. J.; Aggen, D. H.; Zheng, J.; Niederhausern, A.; Alam, S. M.; Balar, O.; Bahadur, N.; Watson, A.; Regazzi, A. M.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results
    Meeting Abstract

    Sternschuss, M.; Guercio, B. J.; Pietzak, E. J.; Ponomarev, M.; Regazzi, A. M.; Quinlan, C.; Aggen, D. H.; Goh, A. C.; Cha, E. K.; Donat, S. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Defining molecular features associated with microsatellite instability and response to immune checkpoint blockade in urothelial carcinoma
    Meeting Abstract

    Alam, S. M.; Teo, M. Y.; Woo, J.; Sarfaty, M.; Funt, S. A.; Aggen, D. H.; Lee, C. H.; Carlo, M. I.; Gandhi, J.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save